Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived more than a year longer than patients who received hormone therapy alone, according to results from a National Institutes of Health-supported randomized controlled clinical trial presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago today (late breaking abstract #2).
The independent Data and Safety Monitoring Committee overseeing the trial had recommended to the National Cancer Institute (NCI), part of NIH, that the study results be made public in December 2013 because a planned interim analysis showed the prolongation in overall survival.
Androgens like testosterone regulate male sex characteristics and can stimulate the growth of prostate cancer cells.
Men received either ADT alone or ADT with the chemotherapy drug docetaxel every three weeks over a period of 18 weeks.
D., clinical director of NCI’s Division of Cancer Treatment and Diagnosis.
“Additionally, these findings are an example of how combining two approved and available treatments can produce a significant improvement in clinical outcome. NCI leads the National Cancer Program and the NIH effort to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.
Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, is world-renowned for its leadership in adult and pediatric cancer treatment and research.
York City police have said they believe that happened as part of a dispute between the Parkside and Southside gangs.
However, because docetaxel is a chemotherapy drug associated with some toxicities, the benefit-to-risk ratio for its early use in combination with ADT is clearly in favor of offering it to patients with high-extent metastatic prostate cancer who are candidates for treatment with docetaxel, according to the trial investigators. “We have strong scientific evidence that patients with the most advanced metastatic prostate cancer benefit from the early addition of docetaxel to testosterone suppression and not waiting until the cancer has progressed with suppressed testosterone therapy.
This is the group of patients who experienced the most benefit in the current analysis. The findings of this study are important both for improving the clinical care we deliver now and in designing new clinical trials as we strive to further improve the lives of men with metastatic prostate cancer.”E3805 was sponsored by NCI and was designed and conducted by the ECOG-ACRIN Cancer Research Group in collaboration with SWOG, Alliance for Clinical Trials in Oncology, and NRG Oncology.
Another man, Elvin Mateo, 21, is also charged in Breeland’s death.
Meanwhile, in a separate case, Cotton is expected to stand trial this July in the killings of two brothers, Angel Berrios, 21, and Abdiel Vazquez-Soto, 19.